Real-World Evidence: Multicenter Efficacy and Toxicity Analysis of Nintedanib With Docetaxel as Second-Line Treatment in Mexican Patients With Advanced Lung Adenocarcinoma.
Rodríguez-Cid JR, Campos-Gomez S, García-Montes V, Magallanes-Maciel M, Flores-Mariñelarena RR, Fernández-Garibay VM, González-Espinoza IR, Ceja-García JP, Cázarez-Price JC, Martínez-Barrera L, Barriguete-Parra L, Zuloaga-Fernandez CJ, Kuri-Exsome R, Suárez-García D, Gonzalez-Villanueva JI, Flores-Anaya N, Acevedo-Delgado JA, Astorga-Ramos AM, Gerson-Cwilich R, Villalobos-Prieto A, Rodríguez-Silva C, Noriega-Iriondo MF, Vázquez-Cortés L, Perales-Rodríguez E, Acosta-Espinoza A, Perez-Lozano Y, Capdeville-García D, Alatorre-Alexander JA.
Rodríguez-Cid JR, et al. Among authors: gerson cwilich r.
JCO Glob Oncol. 2020 Mar;6:462-470. doi: 10.1200/JGO.19.00330.
JCO Glob Oncol. 2020.
PMID: 32196388
Free PMC article.